Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.

‘Everything is on the table,’ including invoking the Defense Production Act, White House COVID Coordinator Zients notes. Results of J&J’s Phase III vaccine trial expected ‘within next few days to a week.’

US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.